| Name | Title | Contact Details |
|---|
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Degraft-Johnson and Associates is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Flo Healthcare is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kinect is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Berkeley Premium Nutraceuticals currently offers six supplements to address issues including sexual health, fatigue, night vision, and cardiovascular health. The Company is also investigating new formulas to assist with other concerns, including prostate